FITC标记的磷酸化过氧化酶活化增生受体γ抗体

供应商 ：上海联迈生物工程有限公司

库存 ：大量

靶点 ：详见说明书

级别 ：1

目录编号 ：LM-3737R-FITC

克隆性 ：多克隆

抗原来源 ：Rabbit

保质期 ：1年

抗体英文名 ：Anti-Phospho-PPAR Gamma (Ser112)/FITC

抗体名 ：Anti-Phospho-PPAR Gamma (Ser112)/FITC

标记物 ：FITC标记

宿主 ：Human, Mouse, Rat, Dog, Pig, Rabbit, Guinea Pig,

适应物种 ：Human, Mouse, Rat, Dog, Pig, Rabbit, Guinea Pig,

免疫原 ：详见说明书

亚型 ：IGg

形态 ：粉末、液体、冻干粉

应用范围 ：Flow-Cyt=1:50-200 IF=1:50-200

浓度 ：1mg/ml

保存条件 ：-20 °C

规格 ：100ul

FITC标记的磷酸化过氧化酶活化增生受体γ抗体

英文名称	Anti-Phospho-PPAR Gamma (Ser112)/FITC
中文名称	FITC标记的磷酸化过氧化酶活化增生受体γ抗体
别    名	PPAR Gamma (Phospho Ser112); PPAR Gamma (Phospho S112); PPAR Gamma (Phospho-Ser112); CIMT1; HUMPPARG; NR1C3; Nuclear receptor subfamily 1 group C member 3; PAX8/PPARG Fusion Gene; Peroxisome Proliferator Activated Receptor gamma; PPAR gamma; PPARG; PPARG1; PPARG2; PPARG3l; PPARG_HUMAN.
规格价格	100ul/2980元 购买        大包装/询价
说 明 书	100ul
产品类型	磷酸化抗体
研究领域	肿瘤  免疫学  细胞凋亡  激酶和磷酸酶
抗体来源	Rabbit
克隆类型	Polyclonal
交叉反应	Human, Mouse, Rat, Dog, Pig, Rabbit, Guinea Pig,
产品应用	Flow-Cyt=1:50-200 IF=1:50-200   not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user.
分 子 量	57kDa
性    状	Lyophilized or Liquid
浓    度	1mg/ml
免 疫 原	KLH conjugated synthesised phosphopeptide derived from human PPAR Gamma around the phosphorylation site of ser112
亚    型	IgG
纯化方法	affinity purified by Protein A
储 存 液	0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存条件	Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
产品介绍	background: This gene encodes a member of the peroxisome proliferator-activated receptor (PPAR) subfamily of nuclear receptors. PPARs form heterodimers with retinoid X receptors (RXRs) and these heterodimers regulate transcription of various genes. Three subtypes of PPARs are known: PPAR-alpha, PPAR-delta, and PPAR-gamma. The protein encoded by this gene is PPAR-gamma and is a regulator of adipocyte differentiation. Additionally, PPAR-gamma has been implicated in the pathology of numerous diseases including obesity, diabetes, atherosclerosis and cancer. Alternatively spliced transcript variants that encode different isoforms have been described. [provided by RefSeq, Jul 2008]. Function: Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. Subunit: "Forms a heterodimer with the retinoic acid receptor RXRA called adipocyte-specific transcription factor ARF6. Interacts with NCOA6 coactivator, leading to a strong increase in transcription of target genes. Interacts with coactivator PPARBP, leading to a mild increase in transcription of target genes. Interacts with FAM120B. Interacts with PRDM16 (By similarity). Interacts with NOCA7 in a ligand-inducible manner. Interacts with NCOA1 LXXLL motifs. Interacts with DNTTIP2, MAP2K1/MEK1, PRMT2 and TGFB1I1. Interacts with PDPK1. Interacts with ASXL1 AND ASXL2. Subcellular Location: Nucleus. Cytoplasm. Tissue Specificity: Highest expression in adipose tissue. Lower in skeletal muscle, spleen, heart and liver. Also detectable in placenta, lung and ovary. DISEASE: Note=Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer.  Defects in PPARG may be associated with susceptibility to obesity (OBESITY) [MIM:601665]. It is a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.  Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) [MIM:604367]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia.  Genetic variations in PPARG can be associated with susceptibility to glioma type 1 (GLM1) [MIM:137800]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Polymorphic PPARG alleles have been found to be significantly over-represented among a cohort of American patients with sporadic glioblastoma multiforme suggesting a possible contribution to disease susceptibility. Similarity: Belongs to the nuclear hormone receptor family. NR1 subfamily.  Contains 1 nuclear receptor DNA-binding domain. Database links: Entrez Gene: 281993 Cow Entrez Gene: 403606 Dog Entrez Gene: 5468 Human Entrez Gene: 19016 Mouse Entrez Gene: 397671 Pig Entrez Gene: 25664 Rat Omim: 601487 Human SwissProt: O18971 Cow SwissProt: Q4U3Q4 Dog SwissProt: P37231 Human SwissProt: P37238 Mouse SwissProt: O62807 Pig SwissProt: O88275 Rat Unigene: 162646 Human Unigene: 3020 Mouse Unigene: 23443 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.  类固醇受体（Steroid Receptors） 过氧化物酶体增殖物激活受体γ（PPARγ）主要存在于白色脂肪组织，PPARγ对于脂肪生成、血糖稳定、炎症反应、动脉粥样硬化和肿瘤等的发生都起到重要的作用。主要在脂肪细胞内表达。PPARγ是噻唑烷二酮类药物（TZDs）作用的药靶，又是脂肪细胞分化的重要调节因子。经研究发现，PPARγ在肥胖及胰岛素抵抗的发病机制中具有十分重要的意义，是治疗糖尿病、肥胖等代谢性疾病的重要药靶。 过氧化物酶体增殖物激活受体γ（PPARγ）属Ⅱ型核受体超家族成员，主要在脂肪细胞内表达。PPARγ是噻唑烷二酮类药物（TZDs）作用的药靶，又是脂肪细胞分化的重要调节因子。现有研究（包括一次于美国加州大学进行的研究）发现PPARγ在肥胖及胰岛素抵抗的发病机制中具有十分重要的意义，是治疗糖尿病、肥胖等代谢性疾病的重要药靶。目前，该受体蛋白质水平的筛选模式已经建立，并正在建立该受体的报告基因的细胞水平筛选评价模式。